Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBT Margin (2016 - 2025)

Regenxbio has reported EBT Margin over the past 12 years, most recently at 221.4% for Q4 2025.

  • Quarterly results put EBT Margin at 221.4% for Q4 2025, up 2027.0% from a year ago — trailing twelve months through Dec 2025 was 113.8% (up 15895.0% YoY), and the annual figure for FY2025 was 113.8%, up 15874.0%.
  • EBT Margin for Q4 2025 was 221.4% at Regenxbio, down from 208.39% in the prior quarter.
  • Over the last five years, EBT Margin for RGNX hit a ceiling of 703.02% in Q4 2022 and a floor of 405.63% in Q1 2024.
  • Median EBT Margin over the past 5 years was 244.04% (2024), compared with a mean of 193.44%.
  • Biggest five-year swings in EBT Margin: soared 62591bps in 2022 and later tumbled -98650bps in 2023.
  • Regenxbio's EBT Margin stood at 77.12% in 2021, then surged by 812bps to 703.02% in 2022, then plummeted by -140bps to 283.48% in 2023, then grew by 15bps to 241.68% in 2024, then grew by 8bps to 221.4% in 2025.
  • The last three reported values for EBT Margin were 221.4% (Q4 2025), 208.39% (Q3 2025), and 331.91% (Q2 2025) per Business Quant data.